Losec MUPS

How to order Losec MUPS

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Losec MUPS on Prescriptsy

Losec MUPS is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Losec MUPS is a branded formulation of omeprazole presented as a multiple unit pellet system (MUPS) tablet, manufactured by AstraZeneca.

Unlike standard omeprazole capsules, each Losec MUPS tablet contains thousands of individually enteric-coated micro-pellets that can be dispersed in water, making the formulation suitable for patients who have difficulty swallowing capsules whole.

This includes children, elderly patients, those with oesophageal strictures or dysphagia, and patients receiving nutrition via nasogastric or gastric tubes.

Losec MUPS is available in the UK in strengths of 10 mg and 20 mg and is a prescription-only medicine (POM).

Omeprazole is a proton pump inhibitor (PPI) that provides profound and sustained suppression of gastric acid secretion.

It is one of the most widely prescribed medicines worldwide and has been in clinical use since the late 1980s.

The MUPS formulation was developed to address a practical clinical need: the delivery of omeprazole to patients unable to swallow intact capsules, without compromising the enteric protection that is essential for the drug's stability and bioavailability.

This page provides a comprehensive clinical overview of Losec MUPS, including how the MUPS technology works, dosing and administration guidance, clinical indications, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Losec MUPS

Before reading further, note the following key safety points about Losec MUPS (omeprazole).

• Do not start omeprazole if you have alarm symptoms (unintentional weight loss, difficulty swallowing, vomiting blood, or black tarry stools) without first having a medical evaluation. PPI therapy can mask symptoms of gastric cancer.
• Do not chew or crush the MUPS tablet. The enteric coating on each micro-pellet must remain intact to protect the drug from stomach acid.
• Omeprazole may reduce the effectiveness of clopidogrel. If you take clopidogrel, inform your prescriber so an alternative PPI can be considered.
• Long-term PPI use should be reviewed regularly to ensure the lowest effective dose is maintained.

What is the MUPS formulation

MUPS stands for multiple unit pellet system.

It is a pharmaceutical technology in which the active ingredient is contained within thousands of tiny pellets (micro-granules), each approximately 0.5 mm in diameter.

Every pellet is individually coated with an enteric polymer (a methacrylic acid copolymer) that is resistant to the acidic environment of the stomach (pH below 5) but dissolves rapidly in the more alkaline conditions of the duodenum and upper jejunum (pH above 5.5).

The key advantage of the MUPS design is that the tablet can be dispersed in liquid without destroying the enteric coating of the individual pellets.

When a Losec MUPS tablet is placed in water, the tablet matrix disintegrates within minutes, releasing a suspension of intact enteric-coated pellets that can be swallowed as a liquid, administered through a nasogastric or percutaneous endoscopic gastrostomy (PEG) tube, or mixed with a small amount of soft food.

Once the pellets reach the duodenum, the enteric coating dissolves, releasing omeprazole for absorption.

This means the MUPS formulation achieves the same bioavailability and clinical efficacy as standard omeprazole capsules.

The MUPS technology also provides more predictable gastric emptying compared with a single-unit capsule.

Because the pellets are small and numerous, they empty from the stomach in a continuous manner along with gastric contents, rather than being retained as a single large unit until the pylorus opens sufficiently.

This results in more consistent drug delivery and absorption, particularly in patients with altered gastric motility.

Clinical indications

Losec MUPS is licensed for the same indications as standard omeprazole capsules.

These include the treatment of gastro-oesophageal reflux disease (GORD), including symptomatic reflux and erosive oesophagitis; healing of gastric and duodenal ulcers; prophylaxis of NSAID-associated gastric and duodenal ulcers in patients at risk; Helicobacter pylori eradication as part of triple therapy with two antibiotics; and management of Zollinger-Ellison syndrome and other pathological hypersecretory conditions.

The choice between Losec MUPS and standard omeprazole capsules is based on the patient's ability to swallow, not on differences in efficacy or safety.

Both formulations deliver the same active ingredient at the same doses and produce the same clinical outcomes.

How Losec MUPS works: mechanism of action

Omeprazole is a substituted benzimidazole that acts as an irreversible inhibitor of the hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) enzyme system, the gastric proton pump.

This enzyme is located on the luminal surface of the parietal cells in the stomach lining and is the final common pathway for the secretion of hydrochloric acid into the gastric lumen, regardless of the stimulus (histamine, acetylcholine, or gastrin).

After absorption from the small intestine, omeprazole is distributed via the bloodstream to the parietal cells, where it selectively accumulates in the highly acidic secretory canaliculi (pH approximately 1.0).

In this acidic environment, the inactive prodrug is converted by acid-catalysed rearrangement to its active form, a tetracyclic sulphenamide.

This active species forms covalent disulphide bonds with specific cysteine residues (Cys-813 and Cys-822) on the alpha subunit of the H+/K+ ATPase, permanently disabling the enzyme.

Because the inhibition is covalent and irreversible, acid secretion can only resume when the parietal cell synthesises new proton pump molecules, a process that takes approximately 3 to 5 days.

This mechanism explains why the acid-suppressing effect of omeprazole outlasts its short plasma half-life (approximately 0.5 to 1 hour).

With once-daily dosing, a cumulative inhibitory effect develops over the first 3 to 5 days, reaching a steady-state suppression of approximately 95% of maximal acid output.

The profound and sustained nature of this acid suppression underlies the clinical superiority of PPIs over H2-receptor antagonists for healing erosive oesophagitis, resolving peptic ulcers, and maintaining symptom remission in GORD.

Clinical evidence and national guidelines

The clinical evidence base for omeprazole, including the MUPS formulation, is extensive.

Omeprazole has been the subject of thousands of clinical trials and has a well-established efficacy and safety profile across all licensed indications.

The bioequivalence of Losec MUPS tablets and standard Losec capsules has been demonstrated in pharmacokinetic studies, confirming that the MUPS formulation provides equivalent systemic exposure and clinical outcomes.

NICE Guideline NG184 (Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management) recommends a full-dose PPI as first-line pharmacological treatment for GORD, with a 4-week course for uninvestigated dyspepsia and 4 to 8 weeks for confirmed oesophagitis.

Maintenance therapy should use the lowest effective dose, and on-demand or intermittent treatment should be considered.

NICE does not specify a particular PPI brand or formulation; the choice is based on clinical judgement, patient preference, cost, and practical considerations such as swallowing ability.

For Helicobacter pylori eradication, NICE recommends triple therapy with a PPI and two antibiotics for 7 days.

Omeprazole-based regimens achieve eradication rates of approximately 80 to 90% in treatment-naive patients.

For peptic ulcer disease, omeprazole 20 mg daily achieves duodenal ulcer healing rates of approximately 95% at 4 weeks and gastric ulcer healing rates of approximately 90% at 8 weeks.

The BNF (British National Formulary) lists Losec MUPS alongside generic omeprazole dispersible tablets and notes that they are particularly suitable for patients who cannot swallow capsules.

The MUPS formulation is widely used in hospitals and care homes where nasogastric tube administration is required.

Dosage and administration

The doses for Losec MUPS are the same as those for standard omeprazole capsules, as both formulations contain omeprazole with equivalent bioavailability. The key difference is in the available administration routes.

Standard oral administration

The tablet may be swallowed whole with a glass of water, taken in the morning, ideally 30 to 60 minutes before breakfast. Do not chew the tablet, as this would damage the enteric coating of the pellets and reduce efficacy.

Dispersed in water

Place the tablet in approximately half a glass (100 ml) of non-carbonated water.

Stir gently until the tablet disintegrates into a suspension of pellets (this usually takes 2 to 5 minutes). Drink the suspension immediately or within 30 minutes of preparation.

Rinse the glass with a further half glass of water and drink this to ensure the full dose is taken.

Do not use carbonated water, milk, or other liquids that may damage the enteric coating or affect the stability of the suspension.

Via nasogastric or gastric tube

Disperse the tablet in approximately 10 ml of water in a catheter-tip syringe of appropriate size.

Allow 1 to 2 minutes for the tablet to disintegrate, then shake the syringe for approximately 10 seconds to ensure a uniform suspension.

Inject the suspension through the tube immediately, then flush the tube with 20 to 30 ml of water to ensure full drug delivery and to prevent tube blockage.

Repeat the dispersion and flush if any pellets remain in the syringe.

Ensure the tube has a minimum internal diameter of 8 French gauge to prevent blockage by the enteric-coated pellets.

Mixed with soft food or fruit juice

For children or adults who prefer not to drink the water suspension, the pellets may be mixed with a spoonful of non-fizzy fruit juice (such as apple or orange juice) or a small amount of soft food (such as yoghurt or apple puree).

The mixture must be swallowed immediately without chewing and should not be stored for later use.

Dosing by indication

GORD: 20 mg once daily for 4 weeks; 20 to 40 mg daily for erosive oesophagitis for 4 to 8 weeks; maintenance 10 to 20 mg daily.

Duodenal ulcer: 20 mg daily for 4 weeks. Gastric ulcer: 20 mg daily for 8 weeks. H.

pylori eradication: 20 mg twice daily for 7 days with two antibiotics. Zollinger-Ellison syndrome: starting dose 60 mg daily, adjusted according to response.

Side effects of Losec MUPS

Common side effects

The side effect profile of Losec MUPS is identical to that of standard omeprazole, as the active ingredient and systemic exposure are the same.

Common side effects include headache, abdominal pain, nausea, diarrhoea, constipation, and flatulence. These are generally mild, self-limiting, and resolve without treatment modification.

Uncommon and rare side effects

Uncommon side effects include dizziness, paraesthesia, dry mouth, altered taste, insomnia, skin rash, and elevated liver enzymes.

Rare but clinically important side effects include interstitial nephritis, hepatitis, severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), blood dyscrasias (thrombocytopenia, leucopenia, agranulocytosis, pancytopenia), and subacute cutaneous lupus erythematosus (SCLE).

Microscopic collagenous colitis has been reported very rarely.

Risks of prolonged use

Long-term PPI therapy has been associated with hypomagnesaemia (usually after 3 or more months of treatment), vitamin B12 deficiency, a modest increase in the risk of osteoporotic fractures, and increased susceptibility to gastrointestinal infections including Clostridium difficile.

Fundic gland polyps may develop during prolonged treatment but are typically benign and reversible upon PPI discontinuation.

Patients on long-term therapy should have periodic review of the ongoing need for treatment and monitoring of relevant blood tests as clinically indicated.

Reporting side effects

Report any suspected adverse reactions to your prescriber or directly via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Warnings and precautions

Exclusion of serious pathology

Before starting omeprazole, serious underlying conditions must be excluded in patients presenting with alarm symptoms (unintentional weight loss, progressive dysphagia, persistent vomiting, haematemesis, melaena, or anaemia).

PPI therapy provides symptomatic relief that may mask the presentation of gastric or oesophageal cancer, potentially delaying diagnosis.

Urgent upper gastrointestinal endoscopy is recommended for patients with alarm symptoms, in accordance with NICE Guideline NG12.

Do not crush or chew

The enteric coating on each micro-pellet is essential for protecting omeprazole from acid degradation in the stomach.

Chewing or crushing the tablet would break this coating, exposing the drug to gastric acid and significantly reducing its bioavailability and effectiveness.

The tablet should be swallowed whole, dispersed in water, or administered through a tube as described in the dosage section.

Drug interactions

Omeprazole inhibits CYP2C19 and may reduce the antiplatelet efficacy of clopidogrel. An alternative PPI (such as lansoprazole or pantoprazole) is generally preferred for patients requiring dual antiplatelet therapy.

Other clinically significant interactions include methotrexate (increased plasma levels), certain antiretrovirals (atazanavir, rilpivirine), and azole antifungals (ketoconazole, itraconazole) whose absorption depends on gastric acidity.

Inform your prescriber and pharmacist of all current medications.

Pregnancy and breastfeeding

Epidemiological data from large cohort studies and meta-analyses have not demonstrated an increased risk of congenital malformations with omeprazole use during pregnancy.

However, omeprazole should be used during pregnancy only when the expected benefit justifies the potential risk.

It is excreted in breast milk in small amounts; discuss the risks and benefits with your prescriber if you are breastfeeding.

Rebound acid hypersecretion

Abrupt discontinuation after prolonged PPI use may result in rebound gastric acid hypersecretion, causing a temporary worsening of reflux symptoms. Gradual dose tapering over 2 to 4 weeks is recommended when stopping long-term therapy.

How to get a Losec MUPS prescription in the UK

Losec MUPS is a prescription-only medicine (POM) in the UK.

It can be prescribed by your GP, hospital specialist, paediatrician, or through an authorised online prescriber registered with the GPhC.

The MUPS formulation is typically prescribed when the standard capsule formulation is not suitable due to swallowing difficulties, nasogastric tube administration, or patient preference.

Generic omeprazole dispersible tablets are also available and are therapeutically equivalent to Losec MUPS. Your pharmacist may dispense a generic version unless the prescriber specifies the brand.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Practical guidance for carers and healthcare professionals

The MUPS formulation is commonly used in care homes, hospitals, and domiciliary settings where patients receive enteral nutrition through tubes.

When administering via a nasogastric or PEG tube, always check the tube's internal diameter is compatible with the pellet size (minimum 8 French gauge recommended).

Use water, not carbonated drinks or acidic liquids, for tube-based dispersal. Flush the tube thoroughly after administration to prevent pellet accumulation and tube blockage.

Document the administration route and any difficulties encountered.

For paediatric patients, the MUPS formulation offers a practical alternative to unlicensed liquid preparations of omeprazole.

Dosing in children is typically based on body weight, and the prescriber should specify the appropriate dose.

Mixing the dispersed pellets with a small amount of fruit juice or soft food can improve palatability and acceptance in young children.

When to seek urgent medical advice

Contact your GP or NHS 111 if symptoms do not improve after the prescribed course, if you develop new or worsening symptoms, or if you notice unexplained weight loss, increasing difficulty swallowing, or a change in bowel habits.

Seek emergency care (call 999 or attend A&E) if you vomit blood, pass black tarry stools, experience severe abdominal pain, or develop signs of a severe allergic reaction such as facial swelling or difficulty breathing.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Losec MUPS 20 mg gastro-resistant tablets, Summary of Product Characteristics (EMC)
• Omeprazole, British National Formulary (BNF)
• NICE NG184: Gastro-oesophageal reflux disease and dyspepsia in adults
• Omeprazole, NHS
• MHRA Yellow Card Scheme